<DOC>
	<DOCNO>NCT02852265</DOCNO>
	<brief_summary>Women currently use start combined oral contraceptive offer study enrollment . Study subject Nexplanon place follow 6 month evaluate continue COC , continue implant , , assess adverse event bleed pattern .</brief_summary>
	<brief_title>Nexplanon COC Combined Use Study</brief_title>
	<detailed_description>The investigator recruit woman see UC Davis medical office contact research office . Potential participant must woman currently COCs intend initiate COCs time office visit . The investigator expect woman recruit office decide initiate COCs continue COC useâ€”these woman offer ability talk research staff study . Visit 1 : Informed consent obtain . As part inform consent , subject educate little data available adverse effect combine COC ENG implant use . The consent form include standardize description side effect bleed profile COCs implant . Subjects also need review package label information Nexplanon sign FDA-required Nexplanon consent . After obtain informed consent , subject screen entry criterion . Medical history obtain . A urine pregnancy test perform . Eligible subject receive prescription desire COC ( need ) Nexplanon contraceptive implant place . A diary dispensed subject document daily bleed , COC use adverse event . Follow-up A follow-up visit occur 1 month ( +1 week ) 3 6 month ( +2 week ) . The diary reviewed copy make keep source documentation . Adverse event determine inquiry diary review . The subject inform study staff use COC want continue use COC ENG implant . At 1 3 month visit , additional diary dispense need . The ENG implant remove upon request time study . A phone call occur approximately 1 week prior 3 6 month visit check status remind subject schedule visit . Study participation complete 6 month follow-up visit . No survey use subject fill . A daily diary use . No blood draw occur study . Data collect study staff include demographic , past medical gynecologic history , prior current contraceptive use , reason use COC ( contraception , medical ) . Because woman enrol already currently use COCs plan start COCs , COC study drug . The study intervention ( study drug ) contraceptive implant . The systemic hormone exposure contraceptive implant minimal relative COC . We would expect increase side effect add contraceptive implant COC user . Of note , primary risk COC use relate estrogen increase risk venous thromboembolic disease . The implant estrogen . All product use study FDA-approved contraception .</detailed_description>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Etonogestrel</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<criteria>Inclusion : Women see UC Davis medical office contact research office . Potential participant must woman currently COCs intend initiate COCs time office visit . Exclusion : Women contraindication use COC contraceptive implant ( Category 3 4 CDC Medical Eligibility Criteria ) exclude . Adults unable consent Individuals yet adult ( infant , child , teenager ) Pregnant woman Prisoners</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>oral contraceptive</keyword>
	<keyword>contraceptive implant</keyword>
	<keyword>contraception</keyword>
	<keyword>adherence</keyword>
	<keyword>adverse event</keyword>
</DOC>